All In Biotech

Drug Trial Radar · NCT07289503

Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

A Randomized, Blinded and Placebo-Control Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Actual

Start

May 27, 2025

Primary completion

Sep 4, 2025

Study completion Jun 27, 2026

Sponsor

Sponsor type
Industry
Collaborators
Abogen Biosciences (Shanghai) Co., Ltd
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • ABO1105Biological

    Formulation for injection

  • PlaceboDrug

    0.9% sodium chloride (normal saline) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of solicited AEs and ARs after a single doseTime frame: up to Day 14
  2. Incidence of unsolicited AEs and ARs after a single doseTime frame: up to Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baise Center For Disease Control & Prevention

    Baise City, Baise, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.